Brief: VBL Therapeutics Announces Patient Dosing Initiated In Randomized, Controlled And Blinded Trial Of Vb-111 In Patients With Recurrent Glioblastoma Multiforme
01/03/2021 14:07
March 1 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VBL THERAPEUTICS ANNOUNCES PATIENT DOSING INITIATED IN
RANDOMIZED, CONTROLLED AND BLINDED TRIAL OF VB-111 IN PATIENTS
WITH RECURRENT GLIOBLASTOMA MULTIFORME
Source text for Eikon: ID:nGNX9VQKLb
Further company coverage: VBLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives